Cargando…
Cost-Effectiveness of Serum Galactomannan Surveillance during Mould-Active Antifungal Prophylaxis
Serial galactomannan (GM) monitoring can aid the diagnosis of invasive aspergillosis (IA) and optimise treatment decisions. However, widespread adoption of mould-active prophylaxis has reduced the incidence of IA and challenged its use. We evaluated the cost-effectiveness of prophylaxis-biomarker st...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227639/ https://www.ncbi.nlm.nih.gov/pubmed/34073588 http://dx.doi.org/10.3390/jof7060417 |
_version_ | 1783712569988481024 |
---|---|
author | Khoo, Ai Leng Zhao, Ying Jiao Tan, Glorijoy Shi En Teng, Monica Yap, Jenny Tambyah, Paul Anantharajah Ng, Chin Hin Lim, Boon Peng Chai, Louis Yi Ann |
author_facet | Khoo, Ai Leng Zhao, Ying Jiao Tan, Glorijoy Shi En Teng, Monica Yap, Jenny Tambyah, Paul Anantharajah Ng, Chin Hin Lim, Boon Peng Chai, Louis Yi Ann |
author_sort | Khoo, Ai Leng |
collection | PubMed |
description | Serial galactomannan (GM) monitoring can aid the diagnosis of invasive aspergillosis (IA) and optimise treatment decisions. However, widespread adoption of mould-active prophylaxis has reduced the incidence of IA and challenged its use. We evaluated the cost-effectiveness of prophylaxis-biomarker strategies. A Markov model simulating high-risk patients undergoing routine GM surveillance with mould-active versus non-mould-active prophylaxis was constructed. The incremental cost for each additional quality-adjusted life-year (QALY) gained over a lifetime horizon was calculated. In 40- and 60-year-old patients receiving mould-active prophylaxis coupled with routine GM surveillance, the total cost accrued was the lowest at SGD 11,227 (USD 8255) and SGD 9234 (USD 6790), respectively, along with higher QALYs gained (5.3272 and 1.1693). This strategy, being less costly and more effective, dominated mould-active prophylaxis with no GM monitoring or GM surveillance during non-mould-active prophylaxis. The prescription of empiric antifungal treatment was influential in the cost-effectiveness. When the GM test sensitivity was reduced from 80% to 30%, as might be anticipated with the use of mould-active prophylactic agents, the conclusion remained unchanged. The likelihood of GM surveillance with concurrent mould-active prophylaxis being cost-effective was 77%. Routine GM surveillance remained cost-effective during mould-active prophylaxis despite lower IA breakthroughs. Cost-saving from reduced empirical antifungal treatment was an important contributing factor. |
format | Online Article Text |
id | pubmed-8227639 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82276392021-06-26 Cost-Effectiveness of Serum Galactomannan Surveillance during Mould-Active Antifungal Prophylaxis Khoo, Ai Leng Zhao, Ying Jiao Tan, Glorijoy Shi En Teng, Monica Yap, Jenny Tambyah, Paul Anantharajah Ng, Chin Hin Lim, Boon Peng Chai, Louis Yi Ann J Fungi (Basel) Article Serial galactomannan (GM) monitoring can aid the diagnosis of invasive aspergillosis (IA) and optimise treatment decisions. However, widespread adoption of mould-active prophylaxis has reduced the incidence of IA and challenged its use. We evaluated the cost-effectiveness of prophylaxis-biomarker strategies. A Markov model simulating high-risk patients undergoing routine GM surveillance with mould-active versus non-mould-active prophylaxis was constructed. The incremental cost for each additional quality-adjusted life-year (QALY) gained over a lifetime horizon was calculated. In 40- and 60-year-old patients receiving mould-active prophylaxis coupled with routine GM surveillance, the total cost accrued was the lowest at SGD 11,227 (USD 8255) and SGD 9234 (USD 6790), respectively, along with higher QALYs gained (5.3272 and 1.1693). This strategy, being less costly and more effective, dominated mould-active prophylaxis with no GM monitoring or GM surveillance during non-mould-active prophylaxis. The prescription of empiric antifungal treatment was influential in the cost-effectiveness. When the GM test sensitivity was reduced from 80% to 30%, as might be anticipated with the use of mould-active prophylactic agents, the conclusion remained unchanged. The likelihood of GM surveillance with concurrent mould-active prophylaxis being cost-effective was 77%. Routine GM surveillance remained cost-effective during mould-active prophylaxis despite lower IA breakthroughs. Cost-saving from reduced empirical antifungal treatment was an important contributing factor. MDPI 2021-05-26 /pmc/articles/PMC8227639/ /pubmed/34073588 http://dx.doi.org/10.3390/jof7060417 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Khoo, Ai Leng Zhao, Ying Jiao Tan, Glorijoy Shi En Teng, Monica Yap, Jenny Tambyah, Paul Anantharajah Ng, Chin Hin Lim, Boon Peng Chai, Louis Yi Ann Cost-Effectiveness of Serum Galactomannan Surveillance during Mould-Active Antifungal Prophylaxis |
title | Cost-Effectiveness of Serum Galactomannan Surveillance during Mould-Active Antifungal Prophylaxis |
title_full | Cost-Effectiveness of Serum Galactomannan Surveillance during Mould-Active Antifungal Prophylaxis |
title_fullStr | Cost-Effectiveness of Serum Galactomannan Surveillance during Mould-Active Antifungal Prophylaxis |
title_full_unstemmed | Cost-Effectiveness of Serum Galactomannan Surveillance during Mould-Active Antifungal Prophylaxis |
title_short | Cost-Effectiveness of Serum Galactomannan Surveillance during Mould-Active Antifungal Prophylaxis |
title_sort | cost-effectiveness of serum galactomannan surveillance during mould-active antifungal prophylaxis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227639/ https://www.ncbi.nlm.nih.gov/pubmed/34073588 http://dx.doi.org/10.3390/jof7060417 |
work_keys_str_mv | AT khooaileng costeffectivenessofserumgalactomannansurveillanceduringmouldactiveantifungalprophylaxis AT zhaoyingjiao costeffectivenessofserumgalactomannansurveillanceduringmouldactiveantifungalprophylaxis AT tanglorijoyshien costeffectivenessofserumgalactomannansurveillanceduringmouldactiveantifungalprophylaxis AT tengmonica costeffectivenessofserumgalactomannansurveillanceduringmouldactiveantifungalprophylaxis AT yapjenny costeffectivenessofserumgalactomannansurveillanceduringmouldactiveantifungalprophylaxis AT tambyahpaulanantharajah costeffectivenessofserumgalactomannansurveillanceduringmouldactiveantifungalprophylaxis AT ngchinhin costeffectivenessofserumgalactomannansurveillanceduringmouldactiveantifungalprophylaxis AT limboonpeng costeffectivenessofserumgalactomannansurveillanceduringmouldactiveantifungalprophylaxis AT chailouisyiann costeffectivenessofserumgalactomannansurveillanceduringmouldactiveantifungalprophylaxis |